Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Re: Thioridazine: Re-evaluating the Risk/Benefit Equation

Re: Thioridazine: Re-evaluating the Risk/Benefit Equation P1: JLS Annals of Clinical Psychiatry (ACLI) pp918-acli-469285 July 8, 2003 10:4 Style file version Nov. 28, 2000 ° C Annals of Clinical Psychiatry, Vol. 15, No. 2, June 2003 ( 2003) Communication Re: Thioridazine: Re-evaluating the Risk/Benefit Equation Anna M. Timell, MD In its March 2000 volume, the Annals of Clinical de pointes and sudden cardiac death. Psychiatrists Psychiatry published my report of four cases of who order EKGs for monitoring of patients on sudden death in developmentally disabled individu- QT-prolonging drugs may have difficulty in obtain- als, in all of which thioridazine had been implicated ing EKGs that have been interpreted in such a as a contributor. Subsequently this author undertook way as to provide the information of interest. Many a monitoring program in which EKGs for all patients EKGs are read without the provision of a measured, taking thioridazine were evaluated. The corrected QT much less corrected, QT interval, and computer- interval was calculated using Bazett’s formula and generated readings are notoriously unreliable. The changes in T wave morphology were noted (flattened, kind of T wave changes that occur with cardiotox- notched, or biphasic). EKGs of a group of patients icity from thioridazine are commonly seen http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Re: Thioridazine: Re-evaluating the Risk/Benefit Equation

Annals of Clinical Psychiatry , Volume 15 (2) – Oct 11, 2004

Re: Thioridazine: Re-evaluating the Risk/Benefit Equation

Abstract

P1: JLS Annals of Clinical Psychiatry (ACLI) pp918-acli-469285 July 8, 2003 10:4 Style file version Nov. 28, 2000 ° C Annals of Clinical Psychiatry, Vol. 15, No. 2, June 2003 ( 2003) Communication Re: Thioridazine: Re-evaluating the Risk/Benefit Equation Anna M. Timell, MD In its March 2000 volume, the Annals of Clinical de pointes and sudden cardiac death. Psychiatrists Psychiatry published my report of four cases of who order EKGs for monitoring of patients on sudden death...
Loading next page...
 
/lp/springer-journals/re-thioridazine-re-evaluating-the-risk-benefit-equation-nNny3aC0OU
Publisher
Springer Journals
Copyright
Copyright © 2003 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1024692426931
Publisher site
See Article on Publisher Site

Abstract

P1: JLS Annals of Clinical Psychiatry (ACLI) pp918-acli-469285 July 8, 2003 10:4 Style file version Nov. 28, 2000 ° C Annals of Clinical Psychiatry, Vol. 15, No. 2, June 2003 ( 2003) Communication Re: Thioridazine: Re-evaluating the Risk/Benefit Equation Anna M. Timell, MD In its March 2000 volume, the Annals of Clinical de pointes and sudden cardiac death. Psychiatrists Psychiatry published my report of four cases of who order EKGs for monitoring of patients on sudden death in developmentally disabled individu- QT-prolonging drugs may have difficulty in obtain- als, in all of which thioridazine had been implicated ing EKGs that have been interpreted in such a as a contributor. Subsequently this author undertook way as to provide the information of interest. Many a monitoring program in which EKGs for all patients EKGs are read without the provision of a measured, taking thioridazine were evaluated. The corrected QT much less corrected, QT interval, and computer- interval was calculated using Bazett’s formula and generated readings are notoriously unreliable. The changes in T wave morphology were noted (flattened, kind of T wave changes that occur with cardiotox- notched, or biphasic). EKGs of a group of patients icity from thioridazine are commonly seen

Journal

Annals of Clinical PsychiatrySpringer Journals

Published: Oct 11, 2004

There are no references for this article.